Michael Leonard Rich, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 32 | 2024 | 931 | 3.000 |
Why?
|
Antitubercular Agents | 28 | 2024 | 1374 | 2.350 |
Why?
|
Clofazimine | 3 | 2024 | 41 | 1.220 |
Why?
|
Nitroimidazoles | 7 | 2024 | 117 | 1.170 |
Why?
|
Rifampin | 5 | 2024 | 341 | 1.060 |
Why?
|
Oxazoles | 7 | 2024 | 199 | 0.870 |
Why?
|
Tuberculosis, Pulmonary | 7 | 2024 | 832 | 0.510 |
Why?
|
Contraception Behavior | 1 | 2015 | 179 | 0.440 |
Why?
|
Sputum | 6 | 2024 | 503 | 0.430 |
Why?
|
Rwanda | 10 | 2015 | 662 | 0.430 |
Why?
|
Family Planning Services | 1 | 2015 | 265 | 0.400 |
Why?
|
Culture | 1 | 2015 | 622 | 0.380 |
Why?
|
Pyrazinamide | 2 | 2024 | 60 | 0.360 |
Why?
|
Directly Observed Therapy | 7 | 2014 | 140 | 0.340 |
Why?
|
Social Support | 4 | 2014 | 2145 | 0.330 |
Why?
|
Mycobacterium tuberculosis | 10 | 2024 | 1905 | 0.310 |
Why?
|
HIV | 2 | 2012 | 1579 | 0.300 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 4 | 2015 | 85 | 0.290 |
Why?
|
Attitude to Health | 1 | 2015 | 2028 | 0.260 |
Why?
|
Residence Characteristics | 2 | 2015 | 2058 | 0.260 |
Why?
|
Motivation | 1 | 2015 | 1990 | 0.250 |
Why?
|
Kazakhstan | 1 | 2024 | 19 | 0.250 |
Why?
|
Medication Adherence | 2 | 2014 | 2163 | 0.230 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2012 | 1894 | 0.230 |
Why?
|
Cycloserine | 1 | 2024 | 118 | 0.230 |
Why?
|
Anti-Retroviral Agents | 2 | 2012 | 1780 | 0.220 |
Why?
|
HIV Infections | 7 | 2015 | 17159 | 0.200 |
Why?
|
Drug Therapy, Combination | 5 | 2024 | 6499 | 0.200 |
Why?
|
Anti-HIV Agents | 2 | 2014 | 4492 | 0.170 |
Why?
|
Drug Resistance, Multiple, Bacterial | 6 | 2017 | 586 | 0.160 |
Why?
|
Fluoroquinolones | 2 | 2022 | 309 | 0.150 |
Why?
|
CD4 Lymphocyte Count | 3 | 2014 | 2569 | 0.150 |
Why?
|
Plague | 1 | 2018 | 21 | 0.150 |
Why?
|
Ofloxacin | 1 | 2017 | 66 | 0.150 |
Why?
|
Rural Population | 6 | 2014 | 2267 | 0.140 |
Why?
|
Treatment Outcome | 19 | 2024 | 64947 | 0.140 |
Why?
|
Russia | 7 | 2014 | 381 | 0.140 |
Why?
|
Administration, Oral | 1 | 2024 | 4044 | 0.140 |
Why?
|
Sex Education | 1 | 2015 | 92 | 0.120 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1093 | 0.120 |
Why?
|
Peru | 5 | 2011 | 870 | 0.110 |
Why?
|
Isoniazid | 1 | 2015 | 283 | 0.110 |
Why?
|
Community Health Services | 2 | 2015 | 654 | 0.110 |
Why?
|
Hospitals, District | 2 | 2013 | 113 | 0.110 |
Why?
|
Prospective Studies | 7 | 2024 | 54263 | 0.100 |
Why?
|
Drug Administration Schedule | 4 | 2015 | 4900 | 0.100 |
Why?
|
Young Adult | 6 | 2024 | 58673 | 0.100 |
Why?
|
Epidemics | 1 | 2018 | 513 | 0.100 |
Why?
|
Tuberculosis | 2 | 2020 | 2003 | 0.100 |
Why?
|
Electrolytes | 2 | 2022 | 280 | 0.100 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2015 | 2127 | 0.090 |
Why?
|
Family Characteristics | 1 | 2016 | 1001 | 0.090 |
Why?
|
Adult | 18 | 2024 | 219847 | 0.090 |
Why?
|
Developed Countries | 1 | 2013 | 443 | 0.090 |
Why?
|
Government Programs | 2 | 2018 | 280 | 0.090 |
Why?
|
Humans | 44 | 2024 | 760261 | 0.090 |
Why?
|
Bacteriological Techniques | 1 | 2011 | 279 | 0.090 |
Why?
|
Drug Repositioning | 2 | 2024 | 231 | 0.090 |
Why?
|
Research Design | 1 | 2006 | 6181 | 0.090 |
Why?
|
Drug Design | 1 | 2015 | 1062 | 0.090 |
Why?
|
Communicable Disease Control | 3 | 2011 | 844 | 0.090 |
Why?
|
Patient Dropouts | 1 | 2012 | 412 | 0.080 |
Why?
|
Gender Identity | 1 | 2015 | 699 | 0.080 |
Why?
|
Female | 22 | 2024 | 391011 | 0.080 |
Why?
|
Clinical Protocols | 3 | 2024 | 1439 | 0.080 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 730 | 0.080 |
Why?
|
Cohort Studies | 8 | 2022 | 41317 | 0.080 |
Why?
|
Male | 21 | 2024 | 359413 | 0.080 |
Why?
|
Developing Countries | 2 | 2013 | 2880 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3822 | 0.070 |
Why?
|
Middle Aged | 11 | 2024 | 220175 | 0.070 |
Why?
|
Viral Load | 2 | 2014 | 3323 | 0.070 |
Why?
|
Microbial Sensitivity Tests | 4 | 2017 | 1952 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2012 | 968 | 0.070 |
Why?
|
Drug Resistance, Multiple | 1 | 2007 | 254 | 0.070 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1500 | 0.070 |
Why?
|
Rural Health Services | 1 | 2009 | 381 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2014 | 5324 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2011 | 966 | 0.060 |
Why?
|
Information Dissemination | 1 | 2013 | 1132 | 0.060 |
Why?
|
Qualitative Research | 1 | 2015 | 2958 | 0.060 |
Why?
|
Retrospective Studies | 14 | 2016 | 80301 | 0.060 |
Why?
|
Retreatment | 1 | 2006 | 600 | 0.060 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2011 | 1349 | 0.060 |
Why?
|
RNA, Viral | 1 | 2012 | 2837 | 0.060 |
Why?
|
Prisoners | 1 | 2006 | 310 | 0.050 |
Why?
|
Algorithms | 1 | 2023 | 13967 | 0.050 |
Why?
|
Child | 6 | 2021 | 79758 | 0.050 |
Why?
|
Patient Compliance | 1 | 2012 | 2689 | 0.050 |
Why?
|
World Health Organization | 2 | 2022 | 1319 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2021 | 58947 | 0.050 |
Why?
|
Program Development | 1 | 2007 | 1297 | 0.050 |
Why?
|
Aged | 8 | 2021 | 168995 | 0.050 |
Why?
|
Program Evaluation | 2 | 2006 | 2494 | 0.050 |
Why?
|
Child Mortality | 2 | 2014 | 206 | 0.040 |
Why?
|
Pregnancy | 3 | 2024 | 29725 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3967 | 0.040 |
Why?
|
Live Birth | 1 | 2024 | 512 | 0.040 |
Why?
|
Latvia | 2 | 2011 | 14 | 0.040 |
Why?
|
Estonia | 2 | 2011 | 54 | 0.040 |
Why?
|
Logistic Models | 2 | 2012 | 13311 | 0.040 |
Why?
|
Philippines | 2 | 2011 | 91 | 0.040 |
Why?
|
Health Services Accessibility | 2 | 2015 | 5396 | 0.040 |
Why?
|
Yersinia pestis | 1 | 2018 | 33 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2005 | 1534 | 0.040 |
Why?
|
Madagascar | 1 | 2018 | 110 | 0.040 |
Why?
|
Depression | 2 | 2014 | 8033 | 0.030 |
Why?
|
Poverty | 1 | 2007 | 2695 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2009 | 4361 | 0.030 |
Why?
|
Adolescent | 6 | 2021 | 87747 | 0.030 |
Why?
|
Pilot Projects | 3 | 2016 | 8553 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2325 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2016 | 597 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1005 | 0.030 |
Why?
|
Prevalence | 3 | 2017 | 15687 | 0.020 |
Why?
|
Public Health | 2 | 2018 | 2655 | 0.020 |
Why?
|
Decision Trees | 1 | 2013 | 506 | 0.020 |
Why?
|
Drug Therapy | 1 | 2014 | 504 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 743 | 0.020 |
Why?
|
Quality of Life | 1 | 2012 | 13300 | 0.020 |
Why?
|
Survival Analysis | 2 | 2014 | 10185 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 7803 | 0.020 |
Why?
|
Registries | 1 | 2005 | 8449 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2012 | 939 | 0.020 |
Why?
|
Ambulatory Care | 2 | 2011 | 2783 | 0.020 |
Why?
|
Heart Failure | 1 | 2013 | 11835 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2024 | 26168 | 0.020 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2009 | 220 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2008 | 208 | 0.020 |
Why?
|
Incidence | 1 | 2006 | 21378 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2007 | 301 | 0.020 |
Why?
|
Microscopy | 1 | 2011 | 881 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 936 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2011 | 1395 | 0.020 |
Why?
|
Risk Factors | 2 | 2016 | 74269 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2012 | 2656 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10340 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6242 | 0.010 |
Why?
|
Regression Analysis | 1 | 2014 | 6361 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2007 | 488 | 0.010 |
Why?
|
Antibiotics, Antitubercular | 1 | 2004 | 101 | 0.010 |
Why?
|
Health Resources | 1 | 2009 | 936 | 0.010 |
Why?
|
Psychometrics | 1 | 2012 | 3049 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4061 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6017 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2003 | 369 | 0.010 |
Why?
|
Health Policy | 1 | 2014 | 2678 | 0.010 |
Why?
|
Echocardiography | 1 | 2013 | 4980 | 0.010 |
Why?
|
Self Report | 1 | 2012 | 3707 | 0.010 |
Why?
|
National Health Programs | 1 | 2004 | 442 | 0.010 |
Why?
|
Time Factors | 2 | 2013 | 40133 | 0.010 |
Why?
|
Data Collection | 1 | 2009 | 3317 | 0.010 |
Why?
|
Leadership | 1 | 2009 | 1372 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39254 | 0.010 |
Why?
|
Treatment Failure | 1 | 2005 | 2646 | 0.010 |
Why?
|
Disease Outbreaks | 1 | 2007 | 1759 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10530 | 0.010 |
Why?
|
Patient-Centered Care | 1 | 2007 | 1416 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8551 | 0.010 |
Why?
|
International Cooperation | 1 | 2003 | 1436 | 0.010 |
Why?
|
Health Personnel | 1 | 2009 | 3310 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15273 | 0.010 |
Why?
|
Child, Preschool | 2 | 2011 | 42034 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15827 | 0.010 |
Why?
|
Clinical Competence | 1 | 2009 | 4786 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20048 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2007 | 3381 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3696 | 0.010 |
Why?
|
Infant | 1 | 2011 | 36030 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2003 | 7468 | 0.000 |
Why?
|